Muse bio, a privately-held company leading the development of next-generation genome engineering capabilities, today announced Dr. John Stuelpnagel, co-founder, first CEO and former COO of Illumina and a well-known genomics industry entrepreneur, will become Chairman of Muse bio’s Board of Directors. In addition to Illumina, Dr. Stuelpnagel has co-founded and held senior leadership roles in several life science companies and brings extensive knowledge in building successful enterprises and commercializing disruptive technologies.
